|
|
| About the manufacturer of
Gabapentin - Neurontin |
Pfizer is an American pharmaceutical company and the developer of
Gabapentin - Neurontin. In 2006, the group is the leader in its
sector globally with a turnover amounting to 48371 billion dollars
(2006), a market capitalization of 219 billion, and staffing of
employees 100000 the world. The group has made an investment in 2006
to 7599 billion dollars in research and development and a profit of
19.3 billion, or 40% of its turnover, an increase of 130% compared
to 2005, from the sale of its products division of public health to
Johnson & Johnson. Pfizer is listed on the NYSE and is part of the
DJIA (Dow Jones Industrial Average).
Charles Pfizer and Charles Erhart founded Pfizer in 1849. After
developing in the United States where Gabapentin - Neurontin, the
company has expanded from its 1951 activities to the world. In 2004,
in connection with the merger Sanofi-Synthélabo and Aventis, the
European Commission has forced it to give in to Pfizer one of its
flagship drugs, Camp to (70 million Euros turnover in 2003). Since
August 2006, the CEO is Jeff Kindler.
On Jan. 22, 2007, he made public a plan for the removal of 10,000
jobs, or about 10% of the group, to be completed in late 2008. They
are regrouping in the United States research and production, and his
organization to rethink the international order to reach $ 2 billion
in savings per year. The group wants to reduce the number of its
factories from 93 in 2007 to 48 at the end of 2008 which might
influence the production of Gabapentin - Neurontin.
|
|
